

11 August 2022

Patient Treatment with Nivolumab and additional products in different types of cancer

Seeking to understand the initiation of patient treatment with Nivolumab and some additional products in different types of cancer:

Response: SACT Information as available from RISOH (Regional Information System Oncology & Haematology) May – June 22

1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma? *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

- **Nivolumab (monotherapy)** <5
- **Nivolumab AND Ipilimumab (combination)** <5

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal Cell Carcinoma? *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

- **Nivolumab (monotherapy)** <5
- **Nivolumab + Ipilimumab** <5
- **Nivolumab + Cabozantinib** <5
- **Avelumab + Axitinib** <5

Again, we are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information.

3. In the past 3 months, how many patients have been initiated* on the following agents for the treatment of upper gastrointestinal cancer (oesophageal cancer, gastric cancer and gastro-oesophageal junction cancer)? *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

- **Nivolumab** : <5
- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)** : <5

Again, we are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information.

11 August 2022

4. Does your Trust participate in any clinical trials for the treatment of Melanoma? If so, please provide the name of each active trial, and the number of patients taking part.

Study Title	Status	No. Patients recruited
A Phase 3, Randomized, Open-label Study of NKTR-214 combined with Nivolumab versus Nivolumab in participants with previously untreated unresectable or metastatic melanoma	Closed to recruitment, but patients on follow-up	<5
A randomised Phase III trial to evaluate the duration of ANti-PD1 monoclonal antibody treatment in patients with metastatic mElanoma (DANTE)	Open	7
Circulating tumour DNA guidEd Therapy for stage IIB/C mElanoma after surgiCal resecTION (DETECTION)	Study in set-up	N/A

Again, use of <5 - we are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information.

5. Does your Trust participate in any clinical trials for the treatment of Renal Cell Carcinoma? If so, please provide the name of each active trial, and the number of patients taking part.

There are currently no active trials recruiting RCC patients. We are however awaiting a decision on site selection regarding one potential study.